Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

We evaluated the profile of the bronchodilatory effect of three inhaled beta2-agonists, 24 microg formoterol, 50 microg salmeterol and 200 microg salbutamol, in patients with stable, moderately severe asthma. Thirty asthmatics (mean+/-SD age 54+/-8 yrs; forced expiratory volume in one second (FEV1) 58+/-12% predicted; reversibility of FEV1 21+/-8% from baseline) participated in a single-centre, double-blind, randomized, single-dose, cross-over study. FEV1 was obtained in baseline condition and 10, 20, 30, 60 min, and every hour up to 12 h after inhalation of the trial drug. Specific airway conductance (sGaw) was measured at baseline condition and 1, 3, 5, 7, 10, 20, 30, 60 min, and every hour up to 12 h after inhalation. Formoterol produced a mean increase in sGaw (as % of baseline) of 44% after 1 min, maximal (135%) after 2 h, and 56% after 12 h. The mean increase in FEV1 was maximal (27%) after 2h, and 10% after 12 h. After salmeterol, mean increase in sGaw amounted to 16% after 3 min, maximal (111%) after 2-4 h, and 58% after 12 h. The mean increase in FEV1 was maximally 25% after 3h, being 11% after 12 h. After salbutamol, mean increase in sGaw was 44% after 1 min and maximal (100%) after 30 min. The peak increase in FEV1 was 25%. We conclude that formoterol (24 microg) and salmeterol (50 microg) had an equal bronchodilatory capacity, which was similar to that of 200 microg salbutamol and lasted for at least 12 h in patients with asthma. However, formoterol had a more rapid onset of action than salmeterol, equal to that of salbutamol.

This article has been cited by other articles:

				R. G. Sturton, A. Trifilieff, A. G. Nicholson, and P. J. Barnes Pharmacological Characterization of Indacaterol, a Novel Once Daily Inhaled 2 Adrenoceptor Agonist, on Small Airways in Human and Rat Precision-Cut Lung Slices J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 270 - 275. [Abstract] [Full Text] [PDF]

				E. Naline, A. Trifilieff, R. A. Fairhurst, C. Advenier, and M. Molimard Effect of indacaterol, a novel long-acting {beta}2-agonist, on isolated human bronchi Eur. Respir. J., March 1, 2007; 29(3): 575 - 581. [Abstract] [Full Text] [PDF]

				C. Battram, S. J. Charlton, B. Cuenoud, M. R. Dowling, R. A. Fairhurst, D. Farr, J. R. Fozard, J. R. Leighton-Davies, C. A. Lewis, L. McEvoy, et al. In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled beta2 Adrenoceptor Agonist with a 24-h Duration of Action J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 762 - 770. [Abstract] [Full Text] [PDF]

				A. R. Rubinfeld, R. Scicchitano, A. Hunt, P. J. Thompson, A. Van Nooten, and O. Selroos Formoterol Turbuhaler as reliever medication in patients with acute asthma Eur. Respir. J., April 1, 2006; 27(4): 735 - 741. [Abstract] [Full Text] [PDF]

				D. Cheung, H. C. J. van Klink, R. Aalbers, and for the OZON study group Improved lung function and symptom control with formoterol on demand in asthma. Eur. Respir. J., March 1, 2006; 27(3): 504 - 510. [Abstract] [Full Text] [PDF]

				J. Wolfe, C. LaForce, B. Friedman, W. Sokol, D. Till, G. Della Cioppa, and A. van As Formoterol, 24 {micro}g bid, and Serious Asthma Exacerbations: Similar Rates Compared With Formoterol, 12 {micro}g bid, With and Without Extra Doses Taken on Demand, and Placebo Chest, January 1, 2006; 129(1): 27 - 38. [Abstract] [Full Text] [PDF]

				C. Jenkins Formoterol as relief medication in asthma: the jury is still out Eur. Respir. J., November 1, 2003; 22(5): 723 - 724. [Full Text] [PDF]

				R H Green, C E Brightling, I D Pavord, and A J Wardlaw Management of asthma in adults: current therapy and future directions Postgrad. Med. J., May 1, 2003; 79(931): 259 - 267. [Abstract] [Full Text] [PDF]

				D Price, D Dutchman, A Mawson, B Bodalia, S Duggan, and P Todd Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose Thorax, September 1, 2002; 57(9): 791 - 798. [Abstract] [Full Text] [PDF]

				N. A. Hanania, A. Sharafkhaneh, R. Barber, and B. F. Dickey {beta}-Agonist Intrinsic Efficacy: Measurement and Clinical Significance Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1353 - 1358. [Full Text] [PDF]

				K. Richter, S. Janicki, R.A. Jorres, and H. Magnussen Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline Eur. Respir. J., May 1, 2002; 19(5): 865 - 871. [Abstract] [Full Text] [PDF]

				J. C. KIPS and R. A. PAUWELS Long-acting Inhaled beta 2-Agonist Therapy in Asthma Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932. [Full Text] [PDF]

				H J van der Woude, T H Winter, and R Aalbers Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting {beta}2 agonists Thorax, July 1, 2001; 56(7): 529 - 535. [Abstract] [Full Text] [PDF]

				A. D. D'Urzo, M. C. De Salvo, A. Ramirez-Rivera, J. Almeida, L. Sichletidis, G. Rapatz, and J. Kottakis In Patients With COPD, Treatment With a Combination of Formoterol and Ipratropium Is More Effective Than a Combination of Salbutamol and Ipratropium : A 3-Week, Randomized, Double-Blind, Within-Patient, Multicenter Study Chest, May 1, 2001; 119(5): 1347 - 1356. [Abstract] [Full Text] [PDF]

				M. Eccles, N. Rousseau, B. Higgins, and L. Thomas Evidence-based guideline on the primary care management of asthma Fam. Pract., April 1, 2001; 18(2): 223 - 229. [Full Text] [PDF]

				A R Guhan, S Cooper, J Oborne, S Lewis, J Bennett, and A E Tattersfield Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects Thorax, August 1, 2000; 55(8): 650 - 656. [Abstract] [Full Text]

				{beta}2-Agonists Can. Med. Assoc. J., November 1, 1999; 161(90111): s28 - 31. [Full Text]

				M. PALMQVIST, T. IBSEN, A. MELLÉN, and J. LÖTVALL Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 244 - 249. [Abstract] [Full Text]